Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial

Abstract Background Low skeletal muscle index (SMI) in metastatic colorectal cancer (mCRC) patients is associated with poor outcomes. The prognostic impact of SMI changes during consecutive palliative systemic treatments is unknown. Methods This is a retrospective analysis of the phase 3 CAIRO3 stud...

Full description

Bibliographic Details
Main Authors: Sophie A. Kurk, Petra H. M. Peeters, Bram Dorresteijn, Pim A. deJong, Marion Jourdan, Geert‐Jan M. Creemers, Frans L. G. Erdkamp, Felix E. deJongh, Peter A. M. Kint, Boelo J. Poppema, Sandra A. Radema, Lieke H. J. Simkens, Bea C. Tanis, Manuel L. R. Tjin‐A‐Ton, Ankie Van Der Velden, Cornelis J. A. Punt, Miriam Koopman, Anne M. May
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Cancer Medicine
Subjects:
Body composition
body mass index
chemotherapy
metastatic colorectal cancer
sarcopenia
skeletal muscle mass
Online Access:https://doi.org/10.1002/cam4.2787

Internet

https://doi.org/10.1002/cam4.2787

Similar Items